By applying in Silico methods to address key questions in the clinical trial design of their micro leadless pacemaker, Medtronic reduced the trial size by 256 patients. This reduction saved an estimated $10 million in costs and shortened the time to enroll critical patients by two years. The accelerated timeline allowed Medtronic to introduce their innovative therapy to the market two years earlier, benefiting 10,000 high-risk patients who would have been ineligible for traditional treatment.